Shares of Enochian BioSciences (NASDAQ: ENOB) soared on Monday after the biopharmaceutical company said the Food and Drug Administration (FDA) accepted its pre-investigational new drug request for a "potential functional cure" of HIV. As of 2:45 p.m. EDT, the biotech stock's price was up more than 100%. Enochian BioSciences said its cellular therapy could potentially allow people with HIV to stop antiviral treatment for long periods.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting